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EXPORT OF PHARMACEUTICAL PRODUCTS UNDER
THE FEDERAL FOOD, DRUG, AND
COSMETIC ACT
The export provision' of the Federal Food, Drug, and Cosmetic Act 2
has been in force since 1906. The Act prohibits the introduction of adulter-
ated or misbranded drugs into interstate commerce.3 The export provision,
however, allows the exportation of such drugs if the product meets the spec-
ifications of the foreign purchaser, does not conflict with the laws of the
importing nation, bears a label stating that it is intended for export, and is
not offered for domestic sale.4 Amendments and judicial interpretations of
the Act have produced a number of inconsistencies in the export law.
In September 1979, the Senate passed a bill5 to amend the Federal
Food, Drug, and Cosmetic Act. If enacted, the Senate bill would result in
the first major revision of U.S. drug export law since 1906.6 The proposed
change comes at a time of intense debate over the export of products not
approved for use by U.S. citizens.7 Some critics contend that the United
States has a moral responsibility not to export products that it deems unsafe
or unhealthy.8 Other commentators argue that each nation has the sover-
eign right to decide for itself which products to import.9
This Note will examine the present export provision of the Federal
Food, Drug, and Cosmetic Act, paying particular attention to the inconsis-
tencies that have developed in the law. It will then analyze the morality
and sovereignty arguments and discuss recent proposals to amend the stat-
1. 21 U.S.C. § 381(d) (1976).
2. Id. §§ 301-392.
3. Id. § 331(a).
4. Id. § 381(d)(1).
5. Drug Regulation Reform Act of 1979, S. 1075, 96th Cong., 1st Sess., 125 CONG. REC.
S13,470 (daily ed. Sept. 26, 1979).
6. See id. § 134.
7. A House subcommittee recently studied U.S. policy concerning the export of banned
products and concluded that it is in need of reform. HOUSE COMM. ON GOVERNMENT OPERA-
TIONS, REPORT ON EXPORT OF PRODUCTS BANNED BY U.S. REGULATORY AGENCIES, H.R.
REP. No. 1686, 95th Cong., 2d Sess. 3 (1978) [hereinafter cited as EXPORT REPORT]. See also
U.S. Export of Banned Products: Hearings Before a Subcomm. of the House Comm. on Govern-
ment Operations, 95th Cong., 2d Sess. (1978) [hereinafter cited as Export Hearings].
8. See, e.g., Drug Regulation Reform 4ct of 1978: Hearings on S. 2755 Before the Sub-
comm. on Health and Scientfic Research of the Senate Comm. on Human Resources, 95th
Cong., 2d Sess. 647-48 (1978) [hereinafter cited as Senate Drug Bill Hearings] (testimony of
Anita Johnson, Environmental Defense Fund).
9. See e.g., id. at 245 (testimony of Joseph A. Califano, Jr., Secretary of HEW).
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ute. Finally, the Note will suggest an export policy that will accommodate
the competing policy considerations and resolve the legislative and judicial
inconsistencies.
THE FEDERAL FOOD, DRUG, AND COSMETIC ACT
The Food and Drugs Act of 1906,10the predecessor of the Federal
Food, Drug, and Cosmetic Act, prohibited the manufacture and shipment
of adulterated or misbranded foods or drugs." Section 2 of the Food and
Drugs Act outlawed the transportation of such articles in interstate or for-
eign commerce, and provided criminal penalties for violations.' 2 A proviso
to that section, however, exempted articles
intended for export to any foreign country and prepared or packed according
to the specifications or directions of the foreign purchaser when no substance
is used in the preparation or packing thereof in conflict with the laws of the
foreign country to which said article is intended to be shipped.' 3
The legislative history of the 1906 Act reveals that in exempting
exports, Congress was concerned about the use of preservatives in packing
meat for overseas shipment. One of the bill's sponsors explained:
The representatives of the great meat-packing and meat-exporting business
called upon me. . . and asked an amendment to the bill ....
• . . [T]he demand in Great Britain, as I understand, is that their meats
shall be received as fresh as it is possible to get meat from this country to
their country, and the only way to ship the meats with safety is to pack them
in borax [boric acid]. They thought that somebody might possibly hold that
borax was deleterious, and therefore if there became a law it might suddenly
interfere, to their great detriment, with their export business. 14
During the floor debate, the Senate hotly disputed the exact scope of
the exemption. Two of the bill's sponsors maintained that the proviso only
covered exports packed in substances that would render them "adulterated"
under the Act, not goods contaminated in their manufacture. Other
Senators, however, expressed the belief that the courts would interpret the
exemption more broadly to include adulterated ingredients. 5 Although
10. Pub. L. No. 59-384, 34 Stat. 768.
11. Id.§§ 1,2.
12. Id.§2.
13. Id. The proviso also stated that articles intended for export but sold or offered for sale
in domestic commerce were not exempt from the Act.
14. Hearings on S.188 andH. 6295 Before the Senate Comm. on Manufactures, 58th Cong.,
2d Sess. 18 (1904) (statement of Sen. McCumber).
15. Mr. HEYBURN. "Prepared" relates to packed.
Mr. SPOONER. "Prepared" does not relate to packed, in my opinion. ...
Mr. SPOONER. The Senators have been explaining to me for some time that it meant
packing in borax.
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one Senator called for a provision clear enough to prevent any confusion,16
the bill passed with the questioned language intact.' 7
Subsequent court decisions confirmed the Senate's fear of judicial mis-
interpretation. In Philadelphia Pickling Co. v. United States, '8 the third cir-
cuit held that federal authorities acted properly in seizing adulterated
tomato paste. The defendant in Philadelphia Pickling had sent the paste
from New Jersey to Pennsylvania for examination prior to shipment to
England, but, upon testing, the goods failed to meet the English standard.
The court emphasized that one of the purposes of the Food and Drugs Act
of 1906 was "to keep adulterated articles completely out of the channels of
interstate commerce."' 9 In dictum, however, the court noted that, due to
the section 2 proviso, "if the paste had met the English test. . . (although it
might have been adulterated according to the United States standard) [it]
would not have been subject to seizure by this government. '20
Mr. HEYBURN. It has no connection with borax, but any injurious packing.
Mr. SPOONER. What would the word "prepared" mean as applied to a bottle con-
taining some drug or to a box of some drug?
Mr. McCUMBER. It certainly would not mean something in the manufacture of the
drug.
Mr. SPOONER. It would not?
Mr. McCUMBER. And no court, I maintain, would hold that when the words "pre-
pared and packed for shipment" were used the word "prepared" could be construed to
mean the ingredients entering into the drug itself.
Mr. SPOONER. I do not think any court would fail to so hold.
40 CONG. REC. 1132 (1906).
16. Mr. SPOONER. I submit ... that the language ought to be so plain that there
should be no difference of opinion about it.
Id.
17. In considering the bill, the House of Representatives also expressed concern with the
packing of meat for overseas shipment. See 38 CONG. REc. 898 (1904). Commenting on the
House version, one representative noted that the export exemption was "especially intended
for the preparation of certain articles for export, such as meats." 40 CONG. REC. 8890 (1906)
(remarks of Rep. Mann) (emphasis added). Shortly before the House passed the bill, one
supporter of the legislation observed that his sole objection to the bill was the export provision.
Id. at 8979 (remarks of Rep. Goulden).
18. 202 F. 150 (3d Cir. 1913). The manufacturer argued that since the product was
intended for export, it was not subject to seizure. The court held, however, that the shipment
across state lines placed the goods in interstate .commerce, and the Act therefore applied
regardless of the purpose of the shipment. Id. at 154.
19. Id. at 152 (emphasis added).
20. Id. at 154. A contemporary observer, however, reading the export proviso in its
intended, narrow sense, stated that its apparent purpose was "to permit the use in certain food
products for export of preservatives which are declared deleterious under the strict rulings of
the Department of Agriculture when applied tofoodproducts intended for consumption in the
United States." W.W. THORNTON, THE LAW OF PURE FOOD AND DRUGS 181 (1912) (empha-
sis added).
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In United States v. Catz American Co., 2 t the ninth circuit went even
further in interpreting the 1906 Act. Catz involved the seizure of a ship-
ment of dried figs intended for export to Italy. The Government claimed
that the goods consisted partly of "filthy, decomposed or putrid vegetable
matter," and the court found the figs "wormy in part."'22 Nevertheless, the
court affirmed a district court decision that the goods were exportable.
According to the Catz court, goods intended for export are not "adulter-
ated" if the manufacturer prepares or packs them in conformity with the
foreign buyer's specifications, provided that the manufacturer does not use
any substance in the preparation or packing that conflicts with the laws of
the importing nation.23 Furthermore, "the words 'prepared or packed'
should be held to mean any condition or grade of the merchandise, includ-
ing any deteriorated state of the goods, considering the class to which they
belong." 24
Thus, as some members of Congress feared, courts interpreted the cru-
cial "prepared and packed" language of the 1906 Act's export provision
broadly, holding that the section 2 exemption applied to all exports,
whether adulterated during manufacture, preparation or packing, or con-
taminated by the course of nature. 25
Decisions such as Philadelphia Pickling and Catz produced several
major inconsistencies in the application of the 1906 Act. Presently, an
American manufacturer may not export adulterated or contaminated food
21. 53 F.2d 425 (9th Cir. 1931).
22. Id.
23. Id. at 426.
24. Id. A district court in 1935 reached a similar result in an unreported case involving
dried apples. The court permitted shipment of the apples to France despite testimony that the
goods contained arsenic and lead and were unsafe for human consumption. f19351 FDA ANN.
REP. 19, reprinted in FOOD LAW INSTITUTE, FEDERAL FOOD, DRUG AND COSMETIC LAW,
ADMINISTRATIVE REPORTS 1907-1949 at 843 (1951).
25. See note 15 supra and accompanying text. Although it did not refer to the 1906 Act's
legislative history, the dissenting opinion in Catz interpreted the section 2 exemption in a
manner consistent with congressional intent. The dissenting judge felt that exports would be
exempt from condemnation only if their contaminated condition was due to their packing or
preparation. 53 F.2d at 426.
In several later cases, courts prohibited the export of contaminated domestic or imported
products that had been seized after entering interstate commerce. See, e.g., United States v.
Kent Food Corp., 168 F.2d 632 (2d Cir.), cert. denied, 335 U.S. 885 (1948) (manufacturer may
not export condemned catsup after interstate shipment for the purpose of domestic sale); 230
Boxes, More or Less, of Fish v. United States, 168 F.2d 361 (6th Cir. 1948) (FDA may seize
imported fish infested with parasitic worms); United States v. 76,552 Pounds of Frog Legs, 423
F. Supp. 329 (S.D. Tex. 1976) (right to export contaminated frog legs denied when record
established some of the goods sold domestically). There have been, however, no recent cases
involving seizures of food or drugs intended solely for export to foreign nations. Apparently,
the FDA learned from experience and stopped trying to prevent such exports, regardless of the
condition of the goods.
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or drugs if he offers them for sale in the United States. If he manufactured
the food or drugs solely for export, however, he may sell them overseas.
Furthermore, a single shipment of adulterated food or drugs may be subject
to partial condemnation and partial approval. For instance, a manufac-
turer may intend to divide a shipment for export to two different countries.
The goods may be found to violate the standards of one of the importing
nations, but not of the other. Although the goods were uniform in their
adulteration, the U.S. Government would only be able to seize that portion
of the shipment intended for export to the nation with the stricter standard.
The Federal Food, Drug, and Cosmetic Act, enacted in 1938,26
repealed the 1906 Food and Drugs Act. 27 One version of the 1938 Act
included foreign trade in its definition of "interstate commerce," which
would have made the new Act equally applicable to exports and domestic
commerce. 28 Industry representatives, however, testified before Congress
that the proposed change would harm U.S. business, create administrative
burdens, and impose American standards on other nations. 29 Congress
thereafter amended the bill to reincorporate the 1906 export provision,30
with one minor change.
3 1
Having thus bypassed an opportunity to resolve the inconsistencies cre-
ated by judicial interpretations of the 1906 Act, Congress proceeded to cre-
ate further incongruities in the drug export law. For example, in 1957
26. Pub. L. No. 75-717, 52 Stat. 1040.
27. Id. § 902(a).
28. See Food, Drugs, and Cosmetics: Hearings on S. 1944 Before the Subcomm ofthe Sen-
ate Comm on Commerce, 73d Cong., 2d Sess. 115 (1933).
29. Id. at 143, 426, 477.
30. See Food, Drugs, and Cosmetics: Hearings on S. 2800 Before the Senate Comn. on
Commerce, 73d Cong., 2d Sess. 1 (1934).
The most telling statement of the entire legislative history occurred during these hearings.
After W.G. Campbell, the Chief of the Food and Drugs Administration, commented that he
thought it "inhuman" to send substandard goods abroad, he received a rebuke from Senator
Hebert: "Mr. Campbell, the provision is not based on any desire to protect the health of
people in the United States, but to protect the interest of manufacturers in the United States.
That isn't the purpose of this bill, it isn't the primary purpose." Id. at 522.
3 . The only change was a requirement that manufacturers label the goods "for export."
21 U.S.C. § 381(d)(1)(C) (1976).
In 1949, the House of Representatives passed an amendment to the export section. H.R.
562, 81st Cong., 1st Sess., 95 CoNo. REc. 7954-55 (1949). The bill required that food and
drugs intended for export meet all of the standards imposed on products sold in domestic
commerce, with three minor exceptions. See H.R. REP. No. 801, 81st Cong., 1st Sess. 3 (1949).
The committee report indicates that the House was concerned with the health of U.S. citizens
abroad who were exposed to adulterated or mislabeled American products. The report also
expresses concern for "international morality," the foreign market for U.S. goods, and "inter-
national good will and peace." Id. at 2. Top officials of several federal agencies, including the
Department of Commerce, expressed support for the measure. Id. at 5-7. The bill, however,
met its demise in a Senate committee. See 95 CONG. REc. 7998 (1949).
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Congress amended section 304(d) of the Act 32 to permit the export of
imported goods condemned after entry into domestic commerce. 33 The
amendment, however, prohibits exportation if the imported goods contain
poisonous or deleterious substances or are mislabeled so as to endanger
human health. 34 Consequently, the amended law prohibits the export of
some contaminated imported goods, but permits the export of similar arti-
cles produced domestically.
3 5
The 1962 drug amendments, 3 6 the first major change in the Food,
Drug, and Cosmetic Act of 1938, did not alter the language of the export
provision.37 Amendments to other sections of the Act, however, added
another inconsistency to the law concerning drug exports. "New drugs,"
which the statute defines as those not recognized as safe and effective or
used only in investigations, 38 are not exportable. 39 Drugs that were subject
to the 1906 Act, however, are exempt from this provision.40 Therefore,
drugs developed before 1938 may be exported even if the FDA has banned
or never approved them for domestic use, and even if they are adulterated
or mislabeled.4 '
32. 21 U.S.C. § 334(d) (1976).
33. Act of Aug. 31, 1957, Pub. L. No. 85-250, 71 Stat. 567. The person seeking release of
the imported article must establish that the adulteration or contamination did not occur after
importation and that he had no reason to believe that the article was in violation of the law.
34. Id See H.R. REP. No. 933, 85th Cong., 1st Sess. 2 (1957). When the goods are to be
returned to the original foreign supplier, however, they may be shipped regardless of their
condition. Id. at 3.
35. Two executive branch officials pointed out that the 1957 bill would result in different
treatment for exports and imports. See id. at 4. Apparently, Congress was unconcerned with
the inconsistency.
36. Act of Oct. 10, 1962, Pub. L. No. 87-781, 76 Stat. 780.
37. The amendments passed in the aftermath of the thalidomide tragedy in Europe, when
Congress was under considerable pressure to prevent such an occurrence in the United States.
See, e.g., 108 CONG. REC. 21,058-59 (1962).
38. 21 U.S.C. § 321(p) (1976).
39. United States v. Yaron Laboratories, Inc., 365 F. Supp. 917 (N.D. Cal. 1972).
40. 21 U.S.C. § 321(p)(1) (1976). See Rutherford v. United States, 542 F.2d 1137 (10th
Cir. 1976); United States v. Articles of Drug Labeled Colchicine, 442 F. Supp. 1236 (S.D.N.Y.
1978).
41. Export Hearings, supra note 7, at 151 (testimony of Dr. Donald Kennedy, Commis-
sioner, Food and Drug Administration). See USV Pharmaceutical Corp. v. Weinberger, 412
U.S. 655, 667 (1973) ("[TJhe legislative history indicates that it was Congress' purpose to
exempt only those drugs that had never been subject to the new drug regulation.").
The most recent amendments to the Food, Drug, and Cosmetic Act, adopted in 1976, pro-
vide special treatment for medical devices. Medical Device Amendments of 1976, Pub. L. No.
94-295, 90 Stat. 539. The export provision is similar to that for drugs, but permits the export of
unapproved, investigational, or banned devices if the Secretary of HEW determines that the
export is not contrary to public health and safety and has the approval of the importing coun-
try. 21 U.S.C. § 381(d)(2) (1976). See H.R. CONF. REP. 1090, 94th Cong., 2d Sess. 66, reprinted
in [1976] U.S. CODE CONG. & AD. NEWS 1103, 1118. The medical devices amendments, there-
fore, produced yet another inconsistency in the seemingly straightforward statute.
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The drug export law has evolved substantially from Congress' original
concern with preserving meat for overseas shipment. Highly questionable
judicial interpretations and piecemeal amendments have created a number
of anomalies in the statute. The law's treatment of products sold in the
domestic market42 and imported goods43 differs from its treatment of goods
produced specifically for export. Drugs lacking FDA approval are exporta-
ble only if developed before 1938.44 As a recent FDA Commissioner
admitted, the law "is so internally inconsistent that it is very hard to know
what the policy is." 45
II
POLICY CONSIDERATIONS
The need for reform of the U.S. drug export law is clear. In order to
develop a consistent policy, Congress will have to reconcile two conflicting
viewpoints. Proponents of moral responsibility contend that the United
States has an obligation not to "dump" its unwanted products abroad.
Conversely, advocates of international sovereignty argue that the United
States should not attempt to police the rest of the world, but rather permit
other nations to import the drugs they consider necessary or desirable.
Each view has its merits and its flaws.
A. MORAL RESPONSIBILITY
From the enactment of the first federal food and drug statute in 1906,
critics have argued that the United States has a responsibility to other
nations in selecting which drugs to export.4 6 Currently, there exist many
compelling reasons for monitoring U.S. drug exports. International trade
has grown exponentially during this century. A number of countries are
only beginning to benefit from global development and still import large
quantities of vital products, including drugs.47 The laws of many countries,
42. See, e.g., United States v. Kent Food Corp., 168 F.2d 632 (2d Cir.), cert. denied 335
U.S. 885 (1948).
43. See, e.g., United States v. 484 Bags, More or Less, 423 F.2d 839 (5th Cir. 1970).
44. See notes 38-41 supra and accompanying text.
45. Export Hearings, supra note 7, at 150 (testimony of Dr. Donald Kennedy).
46. A Congressman who wanted to strike the export exemption from the 1906 Act framed
the question: "[A]s a matter of public policy should we knowingly permit to go away from our
shores an impure food article? This bill says yes. It is not the best advertisement for us as a
people or our goods; it is not the best evidence of high morals." 38 CONG. REC. 900 (1904)
(remarks of Rep. Gaines).
47. For example, the Central American nations import 90% of the raw materials they use
in manufacturing pharmaceutical products. Competitive Problems in the Drug Industry.- Hear-
ings Before the Subcomm. on Monopoly of the Senate Select Comm. on Small Business, 94th
Cong., 2d Sess., pt. 32, at 15,396 (1976) [hereinafter cited as Drug Industry Hearings].
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however, provide little, if any, protection against potentially hazardous
drugs. 4 8 Therefore, critics argue, the developed nations have a moral
responsibility to insure the safety of the drugs they export.49
The absence of a readily available remedy for injuries caused by
adulterated drugs is further reason for controlling the quality of exported
pharmaceuticals. Due to the disproportionate expense involved, it is virtu-
ally certain that no foreign consumer would bring suit against an American
corporation in a U.S. court. Furthermore, foreign governments may be
unable to litigate on behalf of their citizens.50 In some cases, a citizen or
government may be able to obtain jurisdiction over the American corpora-
tion in a foreign court. As a practical matter, however, few governments
will bring such cases, particularly in less-developed countries.51
Unfortunately, unilateral action by the United States would do little to
improve the quality of drugs sold internationally and would harm Ameri-
can business interests. Major pharmaceutical companies based in other
nations will continue to export dangerous drugs, to the detriment of Ameri-
can firms.52 Furthermore, American-based companies will be able to evade
U.S. laws through various devices, such as the establishment of subsidiaries
in countries that have lenient regulations.53
48. Only one-half of the Latin American countries have the legal authority to assess the
scientific value of imported drugs. The Depo-Provera Debate: Hearings Before the House
Select Comm. on Population, 95th Cong., 2d Sess. 198 (1978) [hereinafter cited as Depo-Provera
Hearings]. Latin American nations' policies concerning the disclosure of risks associated with
drugs fall into three categories. Some countries have no laws requiring risk disclosure. Others
have laws that apparently authorize government officials to require disclosure of risks, but
these laws are unclear and rarely enforced. As of 1976, only four Latin American countries
had strict laws, and these were widely violated. Drug Industry Hearings, supra note 47, at
15,372 (statement of Dr. Milton Silverman).
49. In 1975, the World Health Organization (WHO) adopted a "certification scheme on
the quality of pharmaceutical products moving in international commerce." W.H.A. Res.
28.65, 28 WORLD HEALTH ASSEMBLY OFFICIAL RECORDS, pt. 1, 35, 94 (1975). Under this
scheme, exporting countries must either certify that each drug they export is authorized for
sale within their borders or state the reason why it is not approved. They must also provide
assurances that the drug is produced according to manufacturing standards set by WHO. Id.
at 88. The United States and at least 24 other nations have agreed to abide by these standards.
See 31 WHO CHRONICLE (Dec. 1977 Supp.). The European Economic Community has devel-
oped a similar scheme for its member nations. See 10 J. WORLD TRADE LAWS 393 (1976).
50. See, e.g., Pfizer, Inc. v. Lord, 522 F.2d 612 (8th Cir. 1975), cert. denied, 424 U.S. 950
(1976) (foreign governments may not sue as parens patrie for antitrust damages).
51. One congressional witness noted that health agencies in many countries "simply do
not have the clout to compete with other parts of their own government when commercial
interests are involved." Drug Industry Hearings, supra note 47, at 15,385 (testimony of Dr.
Myron E. Wegman, University of Michigan).
52. West Germany, for example, has no restrictions on drug exports. O'Keefe & Czeniek,
4 Study of the Drug Laws of the Federal Republic of Germany, 32 FOOD, DRUG & CosM. L.J.
488, 505 (1971).
53. American companies could also evade the law through what one expert terms "the
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The imposition of severe regulations would also have undesirable
effects on domestic competition. American corporations that have large-
scale international operations and foreign subsidiaries will find it easy to
evade governmental supervision. Smaller U.S. pharmaceutical firms, how-
ever, may be unable to begin or expand foreign operations in order to cir-
cumvent American laws. Finally, a ban or strict limitation of exports would
also have an adverse impact on the balance of trade. 54
B. SOVEREIGNTY
Proponents of the sovereignty position contend that the United States
must respect other nations' choices of what goods to allow into their
marketplaces, rather than appointing itself guardian of the health of per-
sons beyond its borders. Several factors support this position. The FDA's
decisions about drugs are subject to American political pressures and
should not be binding on the rest of the world. Furthermore, the FDA may
not approve certain drugs, such as those used in the treatment of tropical
diseases, because there is no domestic demand for them.55
Finally, the considerations that influence FDA decisions may have lit-
tle or no meaning abroad, since the risk-benefit ratio of many drugs varies
from country to country.56 Depo-Provera, an injectible contraceptive, is a
striking example of such a drug. Because Depo-Provera is associated with
breast tumors, and because other safe and effective methods of contra-
ception are readily available, the FDA has not approved it for use as a
contraceptive.57 Depo-Provera, however, requires only one injection every
three to six months, and is therefore significantly more convenient and
effective in the developing countries than the more traditional methods of
birth control. In such nations, higher birth rates, lower physician-patient
ratios, and fewer available or acceptable means of contraception favor the
drug's use. 58
South Slobovian connection." Under this scheme, an American-manufactured drug is put into
its final form outside of the United States. The other country then becomes the product's
"country of origin," and may export the drug, certifying that it is safe and effective, even if the
FDA does not approve its sale. Drug Regulation Reform Act: Hearings on HR 11611 Before
the Subcomm. on Health and Environment of the House Comm. on Interstate and Foreign Com-
merce, 95th Cong., 2d Sess. 1324 (1978) [hereinafter cited as House Drug BillHearings] (state-
ment of Dr. Milton Silverman).
54. See Export Hearings, supra note 7, at 5-6.
55. Dr. Edgar J. Martin, an FDA official and an expert in tropical medicine, disputed this
rationale during hearings on the Drug Regulation Reform Act of 1978. Senate Drug Bill Hear-
ings, supra note 8, at 1353.
56. Depo-Provera Hearings, supra note 48, at 310-11.
57. Export Hearings, supra note 7, at 93-96. The FDA has approved the drug for U.S. use
in the treatment of endometrial cancer. Id. at 152.
58. About 70 countries approve the use of Depo-Provera as a contraceptive. Id. at 93.
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Nevertheless, the United States cannot abandon all responsibility for
American products. A sizeable percentage of U.S. exports go to countries
that have neither the resources nor the technical capacity to monitor and
test them.59 Furthermore, the FDA admits that its efforts to notify other
countries of its findings regarding particular drug products are often inef-
fective.60
Private channels are also unreliable sources of important medical
information. In a number of cases, American pharmaceutical companies
have used questionable methods in promoting drugs in less-developed
countries. 6' For instance, the FDA only approves the use of the antibiotic
chloramphenicol for life-threatening infections, and U.S. labeling warns
that misuse can cause aplastic anemia, which has a thirty to sixty percent
mortality rate. In Latin America, however, U.S. companies have promoted
the drug as a cure for tonsilitis, bronchitis, and the common cold, fre-
quently without mention of risk.62 In response to such tactics, the develop-
ing nations have begun to request that exporting countries regulate the
information disseminated by multinational corporations. 63
III
PROPOSALS
A unified and workable export policy must strike a balance between
morality and sovereignty considerations, bearing in mind the unequal dis-
tribution of resources among nations. Recent proposals considered by Con-
59. The CIA recently estimated that one-third of all U.S. exports are sent to the less-
developed nations. [1978] INTERNATIONAL TRADE REPORTER'S U.S. EXPORT WEEKLY (BNA)
No. 231, C4.
60. See EXPORT REPORT, supra note 7, at 22-23. See also note 62 infra.
61. See generally Drug Industry Hearings, note 47 supra.
62. House Drug Bill Hearings, supra note 53, at 1324 (testimony of Dr. Milton Silverman).
This drug also provides an example of the inadequacy of providing notice through inter-
national channels. The FDA notified WHO in 1971 that it considered chloramphenicol dan-
gerous and warned that detailed labeling should accompany all sales of the drug. The State
Department notified all U.S. diplomatic posts of the FDA's action. Export Hearings. suora
note 7, at 112-25. Five years later, however, researchers found that pharmaceutical company
detailmen were still misinforming Latin American physicians about the drug. By the middle
of 1977, about one-half of the U.S. firms doing business in Latin America had conformed their
promotion of chloramphenicol to U.S. standards. House Drug Bill Hearings, stpra note 53, at
1324.
63. A report commissioned by the U.N. Economic and Social Council recommended that
"home countries should publicize prohibitions and restrictions on products, or ingredients of
products, found to be hazardous to health, and should consider whether their export should
also be prohibited or made conditional upon specific approval by the importing country."
UNESC, The Report of the Group of Eminent Persons to Study the Role of Multinational
Corporations on Development and on International Relations, E/5500/Add. I (Pt. I), reprinted
in 13 INT'L LEGAL MATERIALS 800, 856 (1974).
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gress are not successful in this respect. The Drug Regulation Reform Act of
1978,64 modeled on the Medical Device Amendments of 1976,65 proposed
significant changes in the export law. The bill permitted the export of those
drugs the FDA has approved for domestic sale. It also allowed the export
of unapproved drugs if the manufacturer obtained a permit from the
FDA.66 To obtain a permit, the manufacturer had to certify that it had
notified the government of the importing nation of the drug's U.S. status
and that the foreign government did not disapprove of the importation.6
7
The bill required the FDA Commissioner to issue the permit unless he or
she determined that the manufacturer had not met one of several specified
conditions for approval.68
The 1978 proposal did not get beyond the subcommittee level in either
House of Congress. In 1979, Senator Kennedy introduced a less compre-
hensive Drug Regulation Reform Act.69 The 1979 bill's original export
provision required a permit for the export of drugs not approved for U.S.
use. The FDA was to issue export permits for unapproved drugs only if
they were to be used to treat or prevent diseases of low incidence in the
United States or if the benefits of use in the foreign country exceeded the
risks.70 Furthermore, the bill required certification from the importing gov-
ernment that it had reviewed scientific data concerning the drug.7 t
After holding hearings on the bill, a Senate committee revised the
64. S.2755, 95th Cong., 2d Sess. (1978), reprinted in Senate Drug Bill Hearings, supra note
8, at 7.
65. Pub. L. No. 94-295, 90 Stat. 539. See note 41 supra.
66. S.2755, 95th Cong., 2d Sess. § 134(a),(c) (1978), Senate Drug Bill Hearings, supra note
8, at 125.
67. Id. § 135(a)(8), Senate Drug Bill Hearings, supra note 8, at 126. The bill also retained
the current law's requirements that the drug meet the foreign purchaser's specifications and
that the label state that the drug is intended solely for export. Id. § 135(a)(6),(7), Senate Drug
Bill Hearings, supra note 8, at 126.
68. These conditions were conformity with the purchaser's specifications, labeling that
indicated that the drug was intended solely for export, the certified approval of the importing
nation, lack of a health hazard, and no untrue material statement in the permit application.
Id. § 135(b), Senate Drug Bill Hearings, supra note 8, at 126-27. The permit was deemed
issued after 30 days unless the Commissioner notified the applicant that further deliberations
were necessary. Id. § 135(c), Senate Drug Bill Hearings, supra note 8, at 127-28.
69. S. 1075, 96th Cong., Ist Sess. (1979).
70. Id sec. 134, § 802(e) (original bill). Although the applicant met one of these condi-
tions, an export permit would not have issued under the original 1979 proposal if the applica-
tion was incomplete or contained a false statement, the drug did not accord to the
specifications of the foreign purchaser, the applicant could not be expected to comply with the
requirements for export, or the export would have been contrary to the public health or result
in the deception of patients. Id. sec. 134, § 802(e)(2)(A)-(D) (original bill).
71. Id. § 802(b)(6)(A) (original bill). The bill also extended the time period for denial of
a permit to 60 days, id. § 802(f), and provided for public comment on all permit applications,
id. § 802(d).
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export provision to more closely parallel the Medical Device Amendments
of 1976.72 The bill, as altered by the subcommittee and passed by the Sen-
ate, allows the export of an unapproved drug if the Secretary of HEW
determines that exportation "is not contrary to public health and safety and
has the approval of the country to which it is intended for export. '73 The
Senate bill also establishes a Task Force on Drug Export Policy and directs
it to develop a Drug Export Policy Plan within 180 days of enactment of the
statute.
74
All of the recent proposals represent advances over the current law.
They impose uniform requirements for all drugs, regardless of the date of
their initial manufacture. 75 They also enable the FDA to prevent exports
because of concerns for public health abroad as well as in the United
States.76 Furthermore, the 1978 bill and the original 1979 proposal
required exported drugs to meet U.S. manufacturing, quality, and labeling
standards. 7 7
None of the proposals, however, adequately reconcile the conflicting
72. See note 65 supra and accompanying text. The committee report on the revised bill
states that one purpose of the legislation is "[t]o create new jobs for American workers and
markets for American drug products by liberalizing drug export policy." S. REP. No, 321, 96th
Cong., 1st Sess. 13 (1979). This may explain why the committee chose to retreat from the more
stringent export provisions of the original 1979 bill. See notes 69-71 supra and accompanying
text.
73. S. 1075, 96th Cong., 1st Sess., sec. 134, § 801(d)(3), 125 CoNG. REC. S13,479 (daily ed.
Sept. 26, 1979) (revised bill). The manufacturer must also comply with the requirements of
§ 801(d)(l) of the present law. Id See text accompanying note 4 supra.
74. S: 1075, 96th Cong., 1st Sess., sec. 134, § 801(d)(3), 125 CONG. REc. S 13,479 (daily ed.
Sept. 26, 1979) (revised bill). The bill orders the task force, in developing a drug export policy,
to consider the differing health needs of other countries; respect risk-benefit assessments made
by foreign governments; assist international efforts to improve health; consider foreign coun-
tries' means of regulating drugs; consider U.S. foreign and economic policies; and suggest the
type of notice that manufacturers should give the FDA before exporting unapproved drugs.
Id.
75. See notes 38-41 supra and accompanying text.
76. See S. 1075, 96th Cong., 1st Sess., sec. 134, § 802(g)(2)(A) (1979) (original bill);
S. 2755, 95th Cong., 2d Sess. § 135(e)(1)(C), Senate Drug Bill Hearings, supra note 8, at 129.
77. The 1979 bill passed by the Senate directs the task force to consider a number of
factors, see note 74 supra, one of which is to "recognize that the manufacture of drugs exported
from the United States should be regulated by standards regarding manufacturing require-
ments and practices that are the same as those applied to the manufacture of drugs approved
for use in this country." S. 1075, 96th Cong., Ist Sess., sec. 134, § 801(d)(3), 125 CoNG. REc.
S 13,479 (daily ed. Sept. 26, 1979) (revised bill). This provision could be read as a statement of
congressional intent to impose U.S. quality standards on exports. Nevertheless, by listing
quality standards as only one of several considerations entering into the Export Policy Plan,
the Senate has not given the task force a clear mandate. For example, the bill also requires the
task force to consider American economic and foreign policies. The task force could deter-
mine that requiring exports to meet U.S. quality standards would conflict with these policies.
Congress should make a clear statement on this issue, either through a specific directive to the
task force or, preferably, through an explicit provision in the statute.
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morality and sovereignty policies. Several considerations should guide
Congress and any future task force in their attempts to develop a coherent
drug export policy.
First, the law should permit the export of all drugs that the FDA has
approved for U.S. use.78 Manufacturers that wish to export unapproved
drugs should notify the importing nation's government whether the drug is
1) new and undergoing evaluation; 2) new and not being evaluated;
3) approved for investigational use only; or 4) banned. The importing
country should also receive full information about the drug, including the
diseases or conditions for which the FDA approves or bans its use, those
conditions or diseases for which it might be used under close medical super-
vision, and possible side effects and their incidence.79 Once the foreign
government has received this information, it will be able to make an
informed judgment whether to allow importation of the drug. Thus, the
importing nation will make the final decision and retain its sovereign right
to accept or ban any pharmaceutical product. At the same time, the United
States can fulfill its moral responsibility to that nation by only allowing
exportation when the Secretary of HEW ascertains that the drug manufac-
turer has presented full and fair information to the importing country.80
Second, the law should require exported drugs to meet the quality
standards established for the domestic sale of pharmaceuticals.81 Thus, a
manufacturer would not be able to export a drug if it contained "filthy,
putrid, or decomposed" substances, if it was packed under insanitary condi-
tions, or if the drug or its container was made of poisonous or deleterious
materials.8 2 Furthermore, the new law should allow drugs to be exported
only if they are of the strength, purity, and quality set forth on their
labels.83
78. Section 505 of the Federal Food, Drug, and Cosmetic Act requires drug manufacturers
to obtain the approval of the Secretary of HEW before introducing any new drug into inter-
state commerce. 21 U.S.C. § 355(a)-(d) (1976). The Secretary has issued regulations for new
drug approval. See 21 C.F.R. § 314 (1979). Pursuant to 21 U.S.C. § 355(i) (1976), the Secre-
tary has also issued regulations exempting drugs intended for investigational use by experts
from the Act's approval requirements. See 21 C.F.R. § 312 (1979).
79. The original 1979 bill required such disclosure. S. 1075, 96th Cong., 1st Sess., sec. 134,
§ 802(b)(6) (1979) (original bill).
80. The 1979 bill passed by the Senate requires an affirmative ruling that exportation is
not contrary to public health and that the importing nation approves of the shipment. See
note 73 supra and accompanying text. This is an improvement over the prior proposals, which
deemed an export permit issued unless the FDA explicitly denied the application within a
specified period. See notes 68 & 71 supra.
81. See 21 U.S.C. § 351 (1976). See also note 77 supra and accompanying text.
82. See 21 U.S.C. § 351(a) (1976).
83. See id. § 35 l(b)-(d). Since the United States has already agreed to ensure compliance
with WHO quality and labeling standards for exported drugs, see note 49 supra, requiring
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Third, all drugs exported from this country should meet U.S. labeling
standards.84 This would compel all manufacturers that export drugs to pre-
vent any false or misleading labeling and to place on labels their names and
places of business, the quantity of the contents, warnings about habit form-
ing ingredients, the established name of each active substance in the drug,
and directions for use. 85 Furthermore, since the Food, Drug, and Cosmetic
Act requires drug manufacturers to present this information on the label
"in such terms as to render it likely to be read and understood by the ordi-
nary individual under customary conditions of purchase and use,"'86
exported drugs would be labeled in the language of the importing country.
In addition, if U.S. law requires patient package inserts for drugs sold
domestically, it should also require them for exported pharmaceuticals. 87
No justification exists for not requiring exporting drug producers to
fully label their products. Label requirements would give consumers more
information concerning the potential hazards of a drug so that they may
make a rational decision about its use. Requiring full disclosure of perti-
nent information certainly would not violate the importing nation's sover-
eignty, provided that the U.S. legislation only established minimum
standards, thereby leaving the foreign government free to require the man-
ufacturer to supply other information on the label. 88
Finally, any new export law should provide special consideration for
investigational drugs. One justification for allowing the export of
compliance with domestic standards would not increase administrative burdens and would
reaffirm the country's commitment to international cooperation in health-related matters.
84. See 21 U.S.C. § 352 (1976). The law should require full compliance with the labeling
requirements for approved as well as unapproved drugs. Drugs routinely used in the United
States may not be safe when used by citizens of other nations. For example, the nutritional
status of persons in developing countries results from diets significantly different from the
typical American diet and can affect reactions to a drug. Genetic factors also have a role.
Perhaps due to their Indian blood, Mexicans are more susceptible to aplastic anemia than are
many U.S. citizens. Drug Industry Hearings, supra note 47, at 15,367. Aplastic anemia is one
severe side effect that may result from misuse of the drug chloramphenicol. See text accompa-
nying note 62 supra. Since most drugs are tested in the United States on American citizens,
some risks may not be apparent at the time of export.
85. See 21 U.S.C. § 352(a)-(f)(1976); 21 C.F.R. § 201 (1979). Both the 1978 and the origi-
nal 1979 bill required that all drug labels include a description of the drug's benefits and risks,
and directions for use, storage, and handling. S. 1075, 96th Cong., 1st Sess., sec. 117,
§ 504(a)(2)(A)-(C) (1979) (original bill); S. 2755, 95th Cong., 2d Sess. § 151(c), Senate Drug Bill
Hearings, supra note 8, at 145-46.
86. 21 U.S.C. § 352(c) (1976).
87. The FDA currently requires these inserts only for oral contraceptives, Depo-Provera,
intrauterine devises, and estrogen products. 21 C.F.R. §§ 310.501, .501a, .502(b)(2), .515
(1979).
88. The Pharmaceutical Manufacturers Association opposed the 1978 bill's labeling
requirements for exported drugs on the ground that the importing nation's laws and regula-
tions could require revised labeling. Senate Drug Bill Hearings, supra note 8, at 362.
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unapproved drugs is that they may treat diseases that are virtually non-
existent in the United States.89 For this reason, American companies may
wish to conduct research in another country. In such cases, the FDA
should require the exporting manufacturer to certify that it is granting any
human subjects used in such research abroad the same privacy and
informed consent rights as are accorded to participants in experiments con-
ducted in this country.90
CONCLUSION
Congress enacted the export provision of the Federal Food, Drug, and
Cosmetic Act in 1906. Since that time, courts and Congress itself have frac-
tured the statute and it now contains unsupportable inconsistencies. For
instance, whether a given drug may be exported may depend on when it
was first introduced into U.S. commerce, or whether it is imported, made
and sold domestically, or manufactured for export. The law also permits
the export of certain drugs that are banned, contaminated, or not approved
for U.S. use.
A new drug export statute must strike a balance between U.S. moral
responsibility for the health of foreign citizens and the sovereignty of other
nations. The Drug Regulation Reform Act of 1979, as passed by the Sen-
ate, fails in its attempt to reconcile these policy considerations. Future
development of drug export policy should have as its cornerstone full dis-
closure of the risks and benefits of exported pharmaceuticals.
Susan D. Goland
89. The original 1979 bill permitted exportation under such conditions. See note 70 supra
and accompanying text.
90. See S. 1075, 96th Cong., 1st Sess., sec. 126, §505(i)(B)(ii),(iii), 125 CONo. REc. S13,475
(daily ed. Sept. 26, 1979) (revised bill).
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